Pediatric myelin oligodendrocyte glycoprotein antibody associated disease following incomplete Kawasaki – a case report with varied association
DOI:
https://doi.org/10.18203/2349-3291.ijcp20263327Keywords:
MOGAD, Kawasaki disease, Optic neuritis, DemyelinationAbstract
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has emerged as a distinct inflammatory demyelinating disorder of the central nervous system. Although relatively rare, growing recognition of this entity has highlighted important differences from multiple sclerosis and neuromyelitis optica spectrum disorder, particularly with respect to clinical phenotype, neuroimaging features, and long-term prognosis. We report a 5-year-old girl who presented with acute, painful, and progressive diminution of vision in the right eye, accompanied by impaired color perception for 3 days. Cerebrospinal fluid analysis was unremarkable, with antibody testing negative for neuromyelitis optica spectrum disorder (NMOSD) and positive for myelin oligodendrocyte glycoprotein (MOG) antibodies. She had a recent history of incomplete Kawasaki disease treated with intravenous immunoglobulin one month prior. While systemic corticosteroids led to partial visual improvement, complete recovery was achieved following intravenous immunoglobulin therapy. This case highlights the importance of assessing MOG-IgG antibodies in pediatric patients presenting with optic neuritis. Precise differentiation from other demyelinating disorders is essential for accurate diagnosis and appropriate management. The overall prognosis is generally favorable.
References
O'Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007;13(2):211-7.
Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89-102.
Wendel EM, Baumann M, Barisic N, Blaschek A, Coelho de Oliveira Koch E, Della Marina A, et al. High association of MOG-IgG antibodies in children with bilateral optic neuritis. Eur J Paediatr Neurol. 2020;27:86-93.
Hor JY, Fujihara K. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol. 2023;14:1260358.
Takai Y, Misu T, Fujihara K, Aoki M. Pathology of myelin oligodendrocyte glycoprotein antibody-associated disease: a comparison with multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. Front Neurol. 2023;14:1209749.
Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-82.
Nakamura M, Ogawa R, Fujimori J, Uzawa A, Sato Y, Nagashima K, et al. Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey. Mult Scler. 2023;29(4-5):530-9.
Kunchok A, Flanagan EP, Snyder M, Saadeh R, Chen JJ, Weinshenker BG, et al. Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD. Mult Scler. 2021;27(4):630-5.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Kavya Rajanna, Gopikishan Sharma

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.